Gyre Therapeutics, Inc. Common Stock (GYRE)
PHARMACEUTICAL PREPARATIONS
Gyre Therapeutics, Inc. Common Stock (GYRE) is listed on Nasdaq, where it has traded since October 31, 2023.
- Listed On
- Nasdaq
- Listed Since
- October 31, 2023
- Employees
- 618
- Market Cap
- $752M
About Gyre Therapeutics, Inc. Common Stock
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 58 institutions reported holding GYRE, with 8.7 million shares worth $57.1 million in aggregate. The largest reported holder was Hsg Holding, with 3.8 million shares worth $24.7 million. Of the 5 largest holders listed below, 2 opened new positions in GYRE, 2 added shares and 1 reduced its position during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Hsg Holding | 3,750,299 | $25M | New position |
| Vanguard | 1,161,936 | $8M | Reduced 3.31% |
| BlackRock | 993,943 | $7M | Added 31.02% |
| Octagon Capital Advisors | 954,416 | $6M | New position |
| Geode Capital Management | 532,950 | $4M | Added 23.54% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is GYRE?
Gyre Therapeutics, Inc. Common Stock (GYRE) is listed on Nasdaq, where it has traded since October 31, 2023.
Who are the largest institutional holders of GYRE?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of GYRE were Hsg Holding, Vanguard and BlackRock.
How many institutions own GYRE?
58 institutions reported a position in GYRE for the quarter ended June 30, 2026, worth $57.1 million in total.
Did institutions buy or sell GYRE last quarter?
Of the 5 largest reported holders, 2 opened new positions in GYRE, 2 added shares and 1 reduced its position during the quarter. Every reported holder and its change is on the SentiSense ownership page for GYRE.
Every reported institutional holder, plus insider and congressional trades in GYRE, on SentiSense.